{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:52:24Z","timestamp":1788990744286,"version":"build-2803163510"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence on homologous recombination repair (HRR) mutation prevalence in prostate cancer (PC) patients and the diagnostic testing path to guide treatment remains limited outside of clinical trials. The objective of this study was to investigate the DNA source, type of tumor tissue, timing for testing in the patient\u2019s disease course, and rate of conclusive results in a real-world population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This was an observational, cohort study, involving 20 Italian cancer centers. The study population included consecutive PC patients undergoing germline, tumor, and\/or plasma circulating tumor DNA (ctDNA) to profile HRR genes between January 1, 2020 and January 31, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1400 PC patients included, 248 (17.7%) showed (likely)pathogenic variants (PVs) in the HRR genes. Most HRR testing was conducted during the metastatic castration-resistant PC (mCRPC)(779, 62.8%). The rate of conclusive results was 89.7% and varied widely according to the type of tumor tissue. The prevalence of HRR alterations was 18.1% in the mCRPC and 13.8% in the hormone-sensitive PC (P\u2009=\u2009.06). The concordance between tumor testing and ctDNA was 83.9%. Interestingly, 4.6% reported ctDNA testing positive but tumor testing negative, leading to important therapeutic implications. The prevalence of positive ctDNA testing was 47.4% vs 10.5%, for testing within 1\u2009month or over 3\u2009months, respectively, from the initiation of a new line of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This large real-world study, through the workflow adopted by clinicians for HRR genomic testing, provides novel insights into the variables influencing the success rate of genomic testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf395","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T13:04:59Z","timestamp":1764335099000},"source":"Crossref","is-referenced-by-count":4,"title":["Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-7286","authenticated-orcid":false,"given":"Lorena","family":"Incorvaia","sequence":"first","affiliation":[{"name":"Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo , Palermo, 90127,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo , Palermo, 90127,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[{"name":"Oncology 3 Unit, Istituto Oncologico Veneto\u2014IOV IRCCS , Padova, 35128,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mammone","sequence":"additional","affiliation":[{"name":"Medical and Translation Oncology, Azienda Ospedaliera S. Maria , Terni, 05100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Santa Chiara Hospital , Trento, 38122,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, Careggi University Hospital , Florence, 50134,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, 70124,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-714X","authenticated-orcid":false,"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Unit of Medical Oncology and Biomolecular Therapy, University of Foggia , Foggia, 71121,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[{"name":"Oncology Unit, ARNAS Civico , Palermo, 90127,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[{"name":"Division of Oncology, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli , 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital , Milan, 20132,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[{"name":"Oncology Unit, Macerata Hospital , Macerata, 62100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, SM delle Grazie Hospital , Pozzuoli, 80078,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Lipari","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale Cannizzaro , Catania, 95126,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Formisano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Stellato","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[{"name":"Oncology 3 Unit, Istituto Oncologico Veneto\u2014IOV IRCCS , Padova, 35128,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori \u2018Fondazione G. Pascale\u2019-IRCCS , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lai","sequence":"additional","affiliation":[{"name":"Oncology 3 Unit, Istituto Oncologico Veneto\u2014IOV IRCCS , Padova, 35128,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Carmelo","family":"Arcara","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, La Maddalena Hospital , Palermo, 90146,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Bronte","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale Cervello Villa Sofia , Palermo, 90146,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tancredi Didier","family":"Bazan Russo","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo , Palermo, 90127,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Colletta","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo , Palermo, 90127,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Gristina","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo , Palermo, 90127,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pepe","sequence":"additional","affiliation":[{"name":"Department of Public Health, University Federico II of Naples , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[{"name":"Department of Public Health, University Federico II of Naples , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Policlinico Umberto I, Sapienza Universit\u00e0 di Roma, Division of Oncology, Department of Radiological, Oncological and Pathological Science, 00161,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Depetris","sequence":"additional","affiliation":[{"name":"University of Turin, AOU Citt\u00e0 della Salute e della Scienza di Torino, Department of Oncology, 10126,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[{"name":"University of Turin, AOU Citt\u00e0 della Salute e della Scienza di Torino, Department of Oncology, 10126,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Badalamenti","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo , Palermo, 90127,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[{"name":"Medical and Translation Oncology, Azienda Ospedaliera S. Maria , Terni, 05100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo , Palermo, 90127,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"2026022006014065300_oyaf395-B1","doi-asserted-by":"crossref","first-page":"100459","DOI":"10.1016\/j.esmoop.2022.100459","article-title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies","volume":"7","author":"Russo","year":"2022","journal-title":"ESMO Open"},{"key":"2026022006014065300_oyaf395-B2","doi-asserted-by":"publisher","first-page":"104738","DOI":"10.1016\/j.ebiom.2023.104738","article-title":"BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype","volume":"95","author":"Fettke","year":"2023","journal-title":"EBioMedicine"},{"key":"2026022006014065300_oyaf395-B3","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026022006014065300_oyaf395-B4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"2026022006014065300_oyaf395-B5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/sj.bjc.6604132","article-title":"Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype","volume":"98","author":"Mitra","year":"2008","journal-title":"Br J Cancer"},{"key":"2026022006014065300_oyaf395-B6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026022006014065300_oyaf395-B7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"2026022006014065300_oyaf395-B8","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"key":"2026022006014065300_oyaf395-B9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41698-024-00672-0","article-title":"The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors","volume":"8","author":"Incorvaia","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026022006014065300_oyaf395-B10","doi-asserted-by":"crossref","first-page":"100235","DOI":"10.1016\/j.esmoop.2021.100235","article-title":"Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge","volume":"6","author":"Bono","year":"2021","journal-title":"ESMO Open"},{"key":"2026022006014065300_oyaf395-B11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/OP-24-00626","article-title":"Implementation of universal germline genetic testing into standard of care for patients with prostate cancer: the time is now","volume":"21","author":"Shore","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"2026022006014065300_oyaf395-B12","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.3390\/cancers15092435","article-title":"Frequency of germline and somatic BRCA1 and BRCA2 mutations in prostate cancer: an updated systematic review and meta-analysis","volume":"15","author":"Valsecchi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026022006014065300_oyaf395-B13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026022006014065300_oyaf395-B14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Network","year":"2015","journal-title":"Cell"},{"key":"2026022006014065300_oyaf395-B15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41698-022-00284-6","article-title":"The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer","volume":"6","author":"Kensler","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026022006014065300_oyaf395-B16","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"2026022006014065300_oyaf395-B17","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026022006014065300_oyaf395-B18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/s1470-2045","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026022006014065300_oyaf395-B19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"key":"2026022006014065300_oyaf395-B20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026022006014065300_oyaf395-B21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"2026022006014065300_oyaf395-B22","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"2026022006014065300_oyaf395-B23","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026022006014065300_oyaf395-B24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.euo.2023.08.004","article-title":"Guidance on establishing a molecular testing pathway for alterations in homologous recombination repair genes in clinical practice for patients with metastatic prostate cancer","volume":"7","author":"Schostak","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026022006014065300_oyaf395-B25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","article-title":"Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib","volume":"83","author":"Loehr","year":"2023","journal-title":"Eur Urol"},{"key":"2026022006014065300_oyaf395-B26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12885-025-13521-5","article-title":"Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies","volume":"25","author":"Mammone","year":"2025","journal-title":"BMC Cancer"},{"key":"2026022006014065300_oyaf395-B27","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for.4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026022006014065300_oyaf395-B28","doi-asserted-by":"publisher","first-page":"e2300654","DOI":"10.1200\/PO.23.00654","article-title":"Toward informed selection and interpretation of clinical genomic tests in prostate cancer","volume":"8","author":"Vandekerkhove","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"2026022006014065300_oyaf395-B29","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00472","article-title":"Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples","volume":"5","author":"Tomlins","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2026022006014065300_oyaf395-B30","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026022006014065300_oyaf395-B31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov"},{"key":"2026022006014065300_oyaf395-B32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/iju.15441","article-title":"Prostate cancer and liquid biopsies: clinical applications and challenges","volume":"31","author":"Urabe","year":"2024","journal-title":"Int J Urol"},{"key":"2026022006014065300_oyaf395-B33","doi-asserted-by":"publisher","first-page":"104076","DOI":"10.1016\/j.esmoop.2024.104076","article-title":"BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus study","volume":"10","author":"Incorvaia","year":"2025","journal-title":"ESMO Open"},{"key":"2026022006014065300_oyaf395-B34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41391-024-00887-z","article-title":"Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (part 2 of 2)","volume":"28","author":"Serritella","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026022006014065300_oyaf395-B35","doi-asserted-by":"publisher","first-page":"102650","DOI":"10.1016\/j.ctrv.2023.102650","article-title":"Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?","volume":"121","author":"Incorvaia","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2026022006014065300_oyaf395-B36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ajcp\/aqv023","article-title":"Identification of factors affecting the success of next-generation sequencing testing in solid tumors","volume":"145","author":"Goswami","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"2026022006014065300_oyaf395-B37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cjp2.203","article-title":"Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer","volume":"7","author":"Gonzalez","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"2026022006014065300_oyaf395-B38","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1158\/1078-0432.CCR-21-2328","article-title":"Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer","volume":"27","author":"Mizuno","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026022006014065300_oyaf395-B39","year":"2026"},{"key":"2026022006014065300_oyaf395-B40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2022.01.006","article-title":"Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing","volume":"33","author":"Terraf","year":"2022","journal-title":"Ann Oncol"},{"key":"2026022006014065300_oyaf395-B41","doi-asserted-by":"crossref","first-page":"e2200329","DOI":"10.1200\/PO.22.00329","article-title":"Addition of germline testing to tumor-only sequencing improves detection of pathogenic germline variants in men with advanced prostate cancer","volume":"6","author":"Berchuck","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026022006014065300_oyaf395-B42","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO precision medicine working group","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann Oncol"},{"key":"2026022006014065300_oyaf395-B43","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","article-title":"Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer","volume":"26","author":"Stopsack","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026022006014065300_oyaf395-B44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"2026022006014065300_oyaf395-B45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"2026022006014065300_oyaf395-B46","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1078-0432.CCR-20-3708","article-title":"BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression","volume":"27","author":"Warner","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026022006014065300_oyaf395-B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2350","article-title":"Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA","volume":"7","author":"Schweizer","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026022006014065300_oyaf395-B48","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J Clin Invest"},{"key":"2026022006014065300_oyaf395-B49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026022006014065300_oyaf395-B50","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun"},{"key":"2026022006014065300_oyaf395-B51","doi-asserted-by":"crossref","first-page":"e2300567","DOI":"10.1200\/PO.23.00567","article-title":"Repeat next-generation sequencing testing on progression in men with metastatic prostate cancer can identify new actionable alterations","volume":"8","author":"Park","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"2026022006014065300_oyaf395-B52","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"2026022006014065300_oyaf395-B53","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.trecan.2021.06.001","article-title":"Technical and biological constraints on ctDNA-based genotyping","volume":"7","author":"Herberts","year":"2021","journal-title":"Trends Cancer"},{"key":"2026022006014065300_oyaf395-B54","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1200\/EDBK_175510","article-title":"Personalizing therapy for metastatic prostate cancer: the role of solid and liquid tumor biopsies","volume":"37","author":"Friedlander","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026022006014065300_oyaf395-B55","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41391-024-00901-4","article-title":"Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)","volume":"28","author":"Armstrong","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf395\/65675397\/oyaf395.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf395\/65675397\/oyaf395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf395\/65675397\/oyaf395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T11:01:52Z","timestamp":1771585312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf395\/8363223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf395","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,12,1]]},"article-number":"oyaf395"}}